ORIC Pharmaceuticals (ORIC) News Today $7.64 -0.39 (-4.86%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.16 (+2.03%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by BrokeragesShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine analysts that are presently covering the firm, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The averaMarch 3 at 4:37 AM | marketbeat.comORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on MondayORIC Pharmaceuticals (NASDAQ:ORIC) will be releasing earnings before the market opens on Monday, March 10.March 3 at 2:55 AM | marketbeat.comWedbush Issues Optimistic Forecast for ORIC EarningsMarch 2 at 1:33 AM | americanbankingnews.comWedbush Lifts Earnings Estimates for ORIC PharmaceuticalsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Wedbush lifted their Q1 2025 earnings estimates for ORIC Pharmaceuticals in a research note issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.50) per share for the quarter, up fromMarch 1 at 6:46 AM | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for ORIC Pharmaceuticals (NASDAQ:ORIC) StockMarch 1 at 3:35 AM | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst UpgradeFebruary 28 at 3:25 AM | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 13.9% Higher on Analyst UpgradeORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst UpgradeFebruary 27, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from GuggenheimGuggenheim reiterated a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday.February 26, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday.February 26, 2025 | marketbeat.comOric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114February 26, 2025 | markets.businessinsider.comOric Pharmaceuticals (ORIC) Gets a Buy from OppenheimerFebruary 26, 2025 | markets.businessinsider.comORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate MilestonesFebruary 25, 2025 | globenewswire.comORIC Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC WainwrightFebruary 23, 2025 | americanbankingnews.comWedbush Issues Pessimistic Outlook for ORIC EarningsFebruary 23, 2025 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Friday.February 22, 2025 | marketbeat.comWedbush Expects Reduced Earnings for ORIC PharmaceuticalsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of ORIC Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now forecasts thFebruary 22, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Earnings BeatORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Strong EarningsFebruary 20, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.6% - Should You Sell?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 5.6% - Here's WhyFebruary 19, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01.February 19, 2025 | marketbeat.comWedbush Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)February 19, 2025 | markets.businessinsider.comOric Pharmaceuticals reports Q4 EPS (51c), consensus (51c)February 18, 2025 | markets.businessinsider.comOric Pharmaceuticals announces upcoming milestonesFebruary 18, 2025 | markets.businessinsider.comORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational UpdatesFebruary 18, 2025 | markets.businessinsider.comORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational UpdatesFebruary 18, 2025 | globenewswire.comHER2+ Non-Small Cell Lung Cancer Market is Predicted to Grow at a CAGR of 13.2% During the Study Period (2020–2034) | DelveInsightFebruary 17, 2025 | finance.yahoo.comWedbush Remains a Buy on Oric Pharmaceuticals (ORIC)February 14, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Biogen (BIIB)February 13, 2025 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.4% - Time to Sell?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.4% - Should You Sell?February 12, 2025 | marketbeat.comORIC Pharmaceuticals stock target holds at $21 by H.C. WainwrightFebruary 11, 2025 | msn.comOric recent weakness a buying opportunity, says JPMorganFebruary 11, 2025 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - What's Next?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Should You Buy?February 11, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Tuesday.February 11, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7% - Time to Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7% - Here's WhyFebruary 10, 2025 | marketbeat.comCantor says Oric accidental release looks ‘very positive’ for mevrometostatFebruary 10, 2025 | markets.businessinsider.comORIC Pharmaceuticals shares surge on potential data leakFebruary 10, 2025 | msn.comGuggenheim Reiterates "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)Guggenheim restated a "buy" rating on shares of ORIC Pharmaceuticals in a report on Monday.February 10, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)February 8, 2025 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)February 8, 2025 | markets.businessinsider.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comJPMorgan Chase & Co. Issues Positive Forecast for ORIC Pharmaceuticals (NASDAQ:ORIC) Stock PriceJPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $19.00 to $21.00 and gave the company an "overweight" rating in a research report on Thursday.February 6, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from BrokeragesORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight brokerages that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month target pFebruary 6, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6% - Still a Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 15.6% - Here's What HappenedFebruary 4, 2025 | marketbeat.comCiti maintains ORIC stock Buy rating, $13 target ahead of PFE dataFebruary 4, 2025 | msn.comCantor Fitzgerald maintains Overweight on ORIC shares, sees upsideFebruary 4, 2025 | msn.comORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early DataFebruary 2, 2025 | seekingalpha.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesJanuary 27, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 5.6% - Should You Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 5.6% - Here's What HappenedJanuary 23, 2025 | marketbeat.comCantor Fitzgerald Estimates ORIC FY2025 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ORIC Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings of (January 23, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 7.8% - Should You Sell?ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.8% - Here's WhyJanuary 16, 2025 | marketbeat.comEquities Analysts Issue Forecasts for ORIC Q2 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 EPS estimates for shares of ORIC Pharmaceuticals in a report released on Monday, January 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.5January 16, 2025 | marketbeat.com Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼0.740.71▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼184▲ORIC Articles Average Week Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Protagonist Therapeutics News Today Centessa Pharmaceuticals News Today Mesoblast News Today CG Oncology News Today Agios Pharmaceuticals News Today Harmony Biosciences News Today IDEAYA Biosciences News Today Belite Bio News Today Janux Therapeutics News Today Galapagos News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
